Adlai Nortye Ltd. Sponsored ADR (ANL) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Adlai Nortye Ltd. has reported its first-half financial results for 2024, including a significant decrease in net loss and a solid cash position expected to support the company for at least the next 12 months. The company has also made key appointments such as Roger Sawhney, M.D. to its Board of Directors and Dr. Archie Tse as Head of R&D, bolstering its strategic and scientific leadership. In their pipeline, they have shared promising data on their cancer therapies, including AN4005, and are on track to present Phase 3 data for their lead candidate, buparlisib, in early 2025.
For further insights into ANL stock, check out TipRanks’ Stock Analysis page.